Evidence map›Paper›PMID 41031196›Full record

ArticleFrontiers in neurology2025

Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses.

Margherita Bellucci, Giovanna Capodivento, Federico Massa, Federica Bozzano, Giacomo Bavestrello, Elena Baroncelli, Corrado Cabona, Antonia Cagnetta, Angelo Schenone, Lucilla Nobbio and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Margherita BellucciDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genoa, Italy.
Giovanna CapodiventoIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Federico MassaDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genoa, Italy.
Federica BozzanoIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Giacomo BavestrelloDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genoa, Italy.
Elena BaroncelliDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genoa, Italy.
Corrado CabonaDivision of Clinical Neurophysiology and Epilepsy Center, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Antonia CagnettaClinic of Hematology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genoa, Italy.
Angelo SchenoneDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genoa, Italy.
Lucilla NobbioIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Luana BenedettiIRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Rituximab (RTX) is a widely used treatment for anti-MAG polyneuropathy, though standardized maintenance strategies are lacking. We aimed to compare two RTX retreatment protocols: (1) a full course (375 mg/m Patients and methods: We retrospectively enrolled 29 patients with anti-MAG polyneuropathy, dividing them into two cohorts: (1) Results and discussion: No significant changes in MRC scores were observed in either cohort. Both cohorts showed a significant reduction in INCAT scores at last follow-up, with a tendency toward greater improvement in Conclusion: A tailored maintenance strategy guided by peripheral CD27+ memory B-cell monitoring enables reduced cumulative RTX exposure while preserving clinical efficacy. This approach may improve cost-effectiveness and reduce treatment burden in patients with anti-MAG polyneuropathy.

Indexed as

anti-MAG polyneuropathyB-cell depletionCD27 B cells monitoringchronic inflammatory neuropathy treatment protocolsrituximab maintenance therapy

Identifiers

PMID41031196
PMCPMC12477036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.